Immunovant Inc.
Cash Flow Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-505.6M | $-413.8M | $-259.3M | $-211.0M | $-156.7M | $-107.4M | $-66.4M | $-28.6M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $409.0K | $377.0K | $231.0K | $193.0K | $126.0K | $65.0K | $21.0K | $10.0K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $55.7M | $49.5M | $41.1M | $32.3M | $34.2M | $18.8M | $7.0M | $1.3M |
| Net Cash from Operating Activities | $-407.3M | $-375.9M | $-214.2M | $-188.2M | $-106.1M | $-83.3M | $-53.4M | $-28.5M |
| Investing Activities | ||||||||
| Capital Expenditures | $8.0K | $759.0K | $360.0K | $197.0K | $254.0K | $210.0K | $31.0K | $52.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-8.0K | $-759.0K | $-360.0K | $-197.0K | $-254.0K | $-210.0K | $-31.0K | $-52.0K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $595.8M | $454.5M | $472.4M | $70.9M | $200.1M | $383.1M | $147.0M | $35.6M |
| Net Change in Cash | $188.1M | $78.6M | $258.8M | $-117.3M | $93.7M | $299.6M | $93.6M | $7.0M |
| Free Cash Flow | $-407.3M | $-376.6M | $-214.6M | $-188.4M | $-106.4M | $-83.5M | $-53.4M | $-28.6M |